TherageniX
London
About TherageniX
TherageniX delivers genes that direct the body to make necessary proteins or substances that aid in tissue regeneration using patented technology. TherageniX's technology employs a proprietary non-viral delivery system to distribute targeted regeneration factor genes (e.g., VEGF and BMP for vascularization and osteogenesis, respectively) as well as autologous bone marrow cells from the patient.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.3M
- Last round: Grant (Aug 2023)
- Website: theragenix.health
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/theragenix-33097 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.